Drug, Biologic Policy Staff Return To US FDA, As RIF Process Hangs In Legal Limbo

The FDA employees with reduction-in-force notice rescissions include some who work on user fee negotiations, but staff still subject to RIFs will not officially separate from the agency this week due to ongoing legal challenges.

Some industry-FDA interactions may be smoother now that the agency has recalled some policy staff that had been subject to reduction-in-force notices. (Shutterstock)

More from US FDA

More from Pathways & Standards